I
InterShunt
Innovative catheter system under development to relieve elevated left atrial pressure in heart failure patients, enhancing daily activity breathing
About InterShunt
Intershunt is a medical technology startup focused on developing innovative solutions for heart failure patients. The company's core product, the InterShunt Percutaneous Atrial Shunt Catheter System, is designed to relieve elevated pressure in the left atrium, which can significantly improve breathing and quality of life for patients. This system is currently under development and has not yet been approved for sale in any geography. Intershunt primarily serves patients suffering from heart failure, a condition affecting over 6 million Americans. The company operates in the medical device market, targeting healthcare providers and institutions that treat heart failure. Intershunt's business model revolves around the development, clinical testing, and eventual commercialization of its catheter system. Revenue will be generated through the sale of the device to hospitals and clinics once it receives regulatory approval. The company aims to address a significant unmet medical need, providing a novel therapeutic option for heart failure patients who currently have limited effective solutions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- St. Louis, United States
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 76.1/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, medical implants, Surgery, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Aug 2024 | $20M | $82M | Undisclosed | ↗ |
| OtherOther financing | Jun 2023 | $0 | — | MedTech Innovator | ↗ |
Growth signals
Latest recorded traffic for InterShunt is 270 monthly website visits, down 59.7% over the last three months. InterShunt's team declined 8.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- AMArsenal Capital Management
avpict
Other known investors5 additional known investors
MedTech Innovator
BioGenerator
BioGenerator Ventures
gener8tor- KSKYTO Technology & Life Science
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about InterShunt on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See InterShunt’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.